Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd (SUDARSHAN) last reported results for the quarter ended Jun 2026, with sales of ₹174 crore and net profit of ₹5.61 crore. The next scheduled event is a merger acquisition on 10 Oct 2026. The stock last traded at ₹37, a market capitalisation of ₹924 crore, on a P/E of 36.8. Over the past 52 weeks the stock has ranged between ₹18.5 and ₹42.8. Figures are as of 6 Oct 2026 and are not real time.
Sudarshan Pharma Industries Ltd share price and key metrics
- Current price
- ₹37
- Market cap
- ₹924 cr
- Stock P/E
- 36.8
- Book value
- ₹6.44
- ROE
- 16.3%
- ROCE
- 15.1%
- Dividend yield
- 0.00%
- 52w high / low
- 42.8/18.5
Metrics as of 6 Oct 2026. Not real time.
Track Sudarshan Pharma Industries Ltd
Cruxal reads every Sudarshan Pharma Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sudarshan Pharma Industries Ltd growth and returns
- 10 Years
- %
- 5 Years
- 29%
- 3 Years
- 15%
- TTM
- 33%
- 10 Years
- %
- 5 Years
- 54%
- 3 Years
- 48%
- TTM
- 13%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 65%
- 1 Year
- 36%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 14%
- Last Year
- 16%
Sudarshan Pharma Industries Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹174 cr, up 20.1% from ₹145 cr a year earlier. Net profit was ₹5.61 cr, up 41.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 116 | 162 | 145 | 169 | 168 | 221 | 174 |
| Expenses | 116 | 108 | 146 | 134 | 160 | 157 | 201 | 159 |
| Operating profit | 13.05 | 7.97 | 15.93 | 11.04 | 9.21 | 10.87 | 20.2 | 15.9 |
| OPM % | 10.15% | 6.89% | 9.86% | 7.60% | 5.45% | 6.47% | 9.14% | 9.12% |
| Other income | -0.85 | 0.51 | -0.81 | 1.21 | 1.86 | 1.52 | 4.13 | 1.22 |
| Interest | 3.7 | 4 | 4.4 | 5.96 | 5.94 | 6.28 | 7.53 | 8.21 |
| Depreciation | 0.67 | 0.63 | 0.83 | 0.88 | 0.9 | 0.91 | 1.09 | 1.41 |
| Profit before tax | 7.83 | 3.85 | 9.89 | 5.41 | 4.23 | 5.2 | 15.71 | 7.5 |
| Tax % | 24.90% | 24.94% | 25.08% | 26.80% | 8.51% | 20.19% | 27.43% | 25.33% |
| Net profit | 5.88 | 2.88 | 7.41 | 3.96 | 3.87 | 4.15 | 11.4 | 5.61 |
| EPS (₹) | 0.24 | 0.12 | 0.31 | 0.17 | 0.17 | 0.18 | 0.45 | 0.23 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sudarshan Pharma Industries Ltd annual results
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 193 | 357 | 461 | 464 | 505 | 703 | 732 |
| Operating profit | 5 | 7 | 11 | 15 | 23 | 40 | 51 | 56 |
| OPM % | 3.2% | 3.7% | 3.1% | 3.2% | 4.9% | 8% | 7% | 8% |
| Net profit | 1 | 3 | 5 | 7 | 11 | 16 | 23 | 25 |
| EPS (₹) | 0.13 | 0.28 | 0.54 | 0.29 | 0.48 | 0.66 | 0.97 | 1.03 |
TTM is the trailing twelve months to the most recent quarter.
Sudarshan Pharma Industries Ltd balance sheet
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 131 |
| Borrowings | 21 | 30 | 31 | 34 | 105 | 171 | 285 |
| Other liabilities | 18 | 47 | 77 | 97 | 67 | 100 | 202 |
| Total liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
| Fixed assets | 6 | 6 | 6 | 20 | 26 | 24 | 104 |
| CWIP | 0 | 0 | 1 | 0 | 2 | 6 | 3 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 0 |
| Other assets | 53 | 93 | 131 | 200 | 242 | 342 | 534 |
| Total assets | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
As reported by the company. Total assets equal total liabilities by construction.
Sudarshan Pharma Industries Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 3 | -4 | -29 | 6 | 35 | -2 |
| Cash from investing | -3 | -1 | -1 | -26 | -5 | -20 | -78 |
| Cash from financing | -0 | -1 | 4 | 66 | -12 | -14 | 79 |
| Net cash flow | -2 | -0 | -1 | 11 | -12 | 0 | -1 |
| Free cash flow | -4 | 1 | -5 | -43 | 2 | 30 | -51 |
| CFO / operating profit | 20% | 50% | -19% | -179% | 36% | 96% | 7% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sudarshan Pharma Industries Ltd operating ratios
| Per year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 15% | 19% | 15% | 14% | 16% | 15% |
| Debtor days | 66 | 114 | 75 | 64 | 96 | 116 | 121 |
| Inventory days | 46 | 49 | 51 | 63 | 74 | 117 | 129 |
| Days payable | 40 | 91 | 80 | 78 | 49 | 76 | 111 |
| Cash conversion cycle | 72 | 72 | 46 | 50 | 122 | 156 | 139 |
| Working capital days | 35 | 29 | 27 | 54 | 62 | 53 | 17 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sudarshan Pharma Industries Ltd shareholding pattern
Promoters held 58.93% at Aug 2026, up from 57.39% at Sep 2025. FIIs 19.88%.
| % held | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% | 58.93% | 58.93% |
| FIIs | 13.07% | 18.45% | 19.49% | 20.79% | 19.78% | 19.95% | 19.38% | 19.88% |
| Government | 0.00% | 0.00% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Public | 29.54% | 24.16% | 23.07% | 21.76% | 22.79% | 22.61% | 21.65% | 21.15% |
| No. of shareholders | 787 | 1,212 | 1,327 | 1,383 | 1,407 | 1,346 | 1,231 | 1,217 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Sudarshan Pharma Industries Ltd events
The next scheduled event is a merger acquisition on 10 Oct 2026.
- Merger acquisitionAcquisition of 76% stake in a pharmaceutical manufacturing plant for backward integration
- Merger acquisitionAcquisition of remaining 30% stake in subsidiary Sudarshan Maven Pharma Private Limited
See the full results calendar for every Indian company reporting in the next 30 days.
Sudarshan Pharma Industries Ltd corporate filings
- Sudarshan Pharma Industries Ltd. terminates acquisition of 50% stake in MedTherapy Biotechnology, USACompany Updatemedium impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd. announced the termination of its proposed acquisition of…
Read the full analysis - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached copy of certificates under Regulation 74(5) of SEBI ( Depository And…
Read the full analysis - The Trading Window of the Company shall remain closed with effect from October 1,2026 until the expiry of 48 hours after the declaration of financial results for the quarter and half year ....Insider Trading / SASTlow impact
- Sudarshan Pharma Industries completes 51% stake sale in Ishwari Healthcare Private LimitedCompany Updatelow impact
Cruxal's analysis: Sudarshan Pharma Industries has finalized the divestment of 209,100 equity shares of Rs…
Read the full analysis - Sudarshan Pharma Industries Ltd announces successful conclusion of 18th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has formally concluded its 18th Annual General Meeting…
Read the full analysis - Sudarshan Pharma Industries Ltd reports 100% shareholder approval for FY2026 financial statements and director re-appointmentAGM/EGMlow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has successfully concluded its 18th Annual General…
Read the full analysis - Sudarshan Pharma Industries Ltd Concludes 18th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has successfully concluded its 18th Annual General…
Read the full analysis - Sudarshan Pharma Industries provides update on ongoing due diligence for 9.50% stake acquisition in Med Therapy Biotechnology Inc., USACompany Updatelow impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has clarified that its proposed acquisition of a…
Read the full analysis - Sudarshan Pharma Industries Limited Promoters Pledge 61.88 Lakh Shares for Loan SecurityInsider Trading / SASTmedium impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has disclosed that members of its promoter group…
Read the full analysis - Sudarshan Pharma Industries Limited announces release of 20 lakh pledged shares by promoterInsider Trading / SASTlow impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has disclosed the release of 20 lakh equity shares…
Read the full analysis - Sudarshan Pharma Industries to acquire 9.50% stake in US-based MedTherapy Biotechnology for market expansionCompany Updatehigh impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has announced the acquisition of a 9.50% equity stake…
Read the full analysis - Sudarshan Pharma Industries Ltd schedules 18th Annual General Meeting for September 22, 2026Company Updatelow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has published the notice for its 18th Annual General…
Read the full analysis - Sudarshan Pharma Industries Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has submitted its Annual Report for the financial year…
Read the full analysis - Sudarshan Pharma Industries Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has submitted its Annual Report for the financial year…
Read the full analysis - Sudarshan Pharma Industries Limited Announces 18th Annual General Meeting for September 22, 2026AGM/EGMlow impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has issued a formal notice for its 18th Annual…
Read the full analysis - Sudarshan Pharma Industries Limited reports pledge of promoter shares for third-party loanInsider Trading / SASTmedium impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has disclosed that promoters Hemal V. Mehta and…
Read the full analysis - Sudarshan Pharma Industries Limited Promoters Pledge 66 Lakh Equity Shares for Loan FacilityInsider Trading / SASTmedium impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has disclosed that its promoters, Hemal V Mehta and…
Read the full analysis - Sudarshan Pharma Industries allots 48.11 lakh equity shares upon FCCB conversionCompany Updatemedium impact
Cruxal's analysis: Sudarshan Pharma Industries has approved the allotment of 48,11,730 fully paid-up equity…
Read the full analysis - Sudarshan Pharma Industries Limited Reports Unaudited Financial Results for Quarter Ended 30th June 2026Company Updatelow impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has released its unaudited financial results for the…
Read the full analysis - Sudarshan Pharma Industries Limited Releases Updated Investor Presentation Highlighting Growth Strategy and Financial PerformanceCompany Updatehigh impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has released an updated investor presentation…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.